Platinum-based chemotherapy remains a cornerstone in the treatment of platinum-sensitive ovarian cancer (PSOC) due to its demonstrated efficacy in prolonging progression-free survival (PFS).1-3 Retreatment with platinum agents, especially in patients who have been exposed to poly ADP-ribose polymerase inhibitors (PARPi) presents challenges with respect to both efficacy and toxicity. Recently, novel targeted therapies, including antibody-drug… Continue reading Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era
Tag: Gynecological Cancer
Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers
This nonrandomized clinical trial examines the clinical activity and adverse events of a novel combination treatment for advanced human papillomavirus–associated cancers.
New standard of care for patients with locally advanced cervical cancer
Cancer, Volume 131, Issue 4, 15 February 2025.
New standard of care for patients with locally advanced cervical cancer
Cancer, Volume 131, Issue 4, 15 February 2025.
Genotypic analysis of human papillomavirus in cervical exfoliated cells from women in Zigong
This study investigated the human papillomavirus (HPV) infection status among women in Zigong from January 2016 to August 2024 and provides a comprehensive statistical analysis of HPV infection characteristics… Continue reading on BioMed Central
TWiV 1193: HPV or not to B
TWiV reviews a facility accident that killed monkeys, new bird blu genotype found in Nevada dairy cattle, Argentina plans to leave WHO, yellow fever on the rise, dynamics of HPV infections in women, and Epstein-Barr virus protein targets B cell receptor for degradation. Hosts:Â Vincent Racaniello, Alan Dove, and Angela Mingarelli Click arrow to playDownload TWiV… Continue reading TWiV 1193: HPV or not to B
Speculum exams unnecessary for HPV screening
Researchers have demonstrated that self-sampling is just as effective as speculum-based testing for HPV detection.
Gene therapy shows clinical benefit in patients with a debilitating disorder caused by HPV
An NCI clinical trial showed that an experimental gene therapy called PRGN-2012 may be an effective treatment for recurrent respiratory papillomatosis, which is caused by HPV 6 and HPV 11.
Genetic variations and carcinogenicity analysis of E6/E7 oncogenes in HPV31 and HPV35 in Taizhou, China
The purpose of this study was to investigate the genetic variations in the E6 and E7 oncogenes of HPV31 and HPV35, and to explore their potential role in cervical cancer risk among women in Taizhou, China. Continue reading on BioMed Central
Ovarian cancer discovery could turn failed treatment into lifesaver
Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.